Dr Reddy's sticks to 20%+ EBITDA margin for FY27.

Dr. Reddy's Laboratories Limited

has reiterated its FY27 EBITDA margin guidance of 20 percent and above. Q2 margins stood at 20.6 percent. The company maintained its full-year EBITDA margin outlook at 20 percent plus. Second-quarter margins came in at 20.6 percent. The guidance and reported figure show steady profitability for the pharma firm. Key numbers are the 20 percent plus FY27 EBITDA margin guidance and the 20.6 percent Q2 margin. These may support near-term interest in the stock on margin stability. Peers such as Sun Pharma, Cipla and Divi's Laboratories could face relative comparison on profitability trends. Risks include higher input costs or pricing pressure. Competitors listed: Sun Pharma, Cipla, Divi's Laboratories. We have no financial interest in this news.